Literature DB >> 1515685

Evaluation of autonomic function.

P A Low1.   

Abstract

Clinical laboratory evaluation of adrenergic function is lacking in sensitivity. Recent studies suggest that components of the Valsalva maneuver can be used to evaluate adrenergic function. Late phase II and phase IV are primary regulated by peripheral and cardiac sympathetic activity, respectively. With progressive adrenergic failure there is a loss of IIl, an increase in IIe and a loss of IV in that order. Baroreflex gain can be described by the heart period/blood pressure (BP) response. An alternative approach of expressing latency instead of gain is of interest but is of uncertain validity. Evaluation of heart rate recordings in the frequency domain using power spectral analysis can be used to study parasympathetic/sympathetic balance in humans. Its value as a clinical test remains to be established. Prolonged tilt is a sensitive and probably specific test of vasodepressor syncope. Isoproterenol infusion during tilt is of doubtful specificity.

Entities:  

Mesh:

Year:  1992        PMID: 1515685

Source DB:  PubMed          Journal:  Curr Opin Neurol Neurosurg        ISSN: 0951-7383


  3 in total

1.  Treatment of painful sensory neuropathy with tiagabine: a pilot study.

Authors:  V Novak; R Kanard; J T Kissel; J R Mendell
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

2.  Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes.

Authors:  Vera Novak; David Last; David C Alsop; Amir M Abduljalil; Kun Hu; Lukas Lepicovsky; Jerry Cavallerano; Lewis A Lipsitz
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

3.  Altered Phase Interactions between Spontaneous Blood Pressure and Flow Fluctuations in Type 2 Diabetes Mellitus: Nonlinear Assessment of Cerebral Autoregulation.

Authors:  Kun Hu; C K Peng; Norden E Huang; Zhaohua Wu; Lewis A Lipsitz; Jerry Cavallerano; Vera Novak
Journal:  Physica A       Date:  2008-04-01       Impact factor: 3.263

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.